(1-苄基-1H-苯并咪唑-2-基)甲醇 | 6646-70-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: (1-苄基-1H-苯并咪唑-2-基)甲醇
• 英文名称: (1-benzyl-1H-benzo[d]imidazol-2-yl)methanol
• 英文别名: (1-benzyl-1H-benzimidazol-2-yl)methanol；(1-benzylbenzimidazol-2-yl)methanol
• CAS: 6646-70-4
• 化学式: C₁₅H₁₄N₂O
• mdl: MFCD00182174
• 分子量: 238.289
• InChiKey: BMKLUFBUYHXGGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  38
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312+P330,P302+P352,P304+P340+P312,P305+P351+P338,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (1-苄基-1H-苯并咪唑-2-基)甲醇 在 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 18.0h， 生成 1-苄基-2-氯甲基-1H-苯并咪唑
  参考文献：
  名称：

  [EN] BENZIMIDAZOLES FOR THE TREATMENT OF CANCER
  [FR] BENZIMIDAZOLES POUR LE TRAITEMENT D'UN CANCER

  摘要：

  本发明涉及新型取代苯并咪唑和立体异构体形式，以及这些化合物的前药、溶剂化合物、水合物和/或药学上可接受的盐，以及含有至少一种这些取代苯并咪唑的药物组合物，与药学上可接受的载体、赋形剂和/或稀释剂一起。已经确定这些新型取代苯并咪唑结合到PDEδ的藤黄素结合口袋，对于通过抑制PDEδ与K-Ras的结合以及通过改变其定位导致细胞死亡或抑制增殖而对癌症的预防和治疗是有用的。

  公开号：

  WO2014027053A1
• 作为产物：
  描述：

  N-acetoxy-2-(acetoxymethyl)benzimidazole 在 sodium hydroxide 、 苄基三乙基氯化铵 、 水 、 potassium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 0.5h， 生成 (1-苄基-1H-苯并咪唑-2-基)甲醇
  参考文献：
  名称：

  Alternate Method for the Synthesis of N‐Alkyl/aralkyl‐2‐(α‐hydroxy Alkyl/aralkyl)benzimidazoles via Regiospecific Acetylation

  摘要：

  Acetylation of 1H-2-(alpha-hydroxyalkyl/aryl) benzimidazoles 2 with Ac2O results in the regiospecific formation of O-acetoxy derivative 3, which on alkylation with alkylating agents in nonaqueous media under phase-transfer catalytic conditions affords N-alkyl derivatives 4. The latter, on hydrolysis in an aqueous basic medium, results in the title compounds 5 in good yields in high purity. Alternatively, 5 can also be obtained by reduction of 1-substituted-2-acetyl/benzoylbenzimidazoles 8 using NaBH4.

  DOI：

  10.1080/00397910701265556

文献信息

• “All-water” chemistry of tandem N-alkylation–reduction–condensation for synthesis of N-arylmethyl-2-substituted benzimidazoles
  作者：Damodara N. Kommi、Dinesh Kumar、Rohit Bansal、Rajesh Chebolu、Asit K. Chakraborti

  DOI：10.1039/c2gc36377a

  日期：——

  also exerts a beneficial effect in the condensation of N-monobenzylated o-phenylenediamines with aldehydes. The water-assisted C–N bond formation chemistry led to metal/base-free synthesis of N-monobenzylated o-nitroanilines and N-monobenzylated o-phenylenediamines. The indispensable/advantageous role of water in the various stage of the N-alkylation–reduction–condensation process exemplifies an ‘all-water’

  设计了水辅助串联N-烷基化-还原-缩合工艺，作为一锅合成N-芳基甲基-2-取代的新合成途径苯并咪唑。 水 通过氢键介导的“亲电-亲核双重”发挥关键和必不可少的作用 激活促进邻硝基苯胺的选择性N-单苄基化，以替代基于过渡金属的C–N键形成（胺化）化学方法，并形成以区域确定的方式将取代基布置在苯并咪唑基团上的基础。水在N-单苄基化邻苯二胺与醛类。水辅助的C–N键形成化学反应导致N /单苄基化的邻硝基苯胺和N-单苄基化的邻苯二胺的无金属/碱合成。的不可或缺/有利的作用水在N-烷基化-还原-缩合过程的各个阶段中，都可以举例说明“全水”化学合成N-芳基甲基-2-取代基的过程苯并咪唑。
• Discovery of benzimidazole derivatives as potent and selective aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with glucose consumption improving activity
  作者：Zonghui Ma、Ling Jiang、Bingyan Li、Dailin Liang、Yu Feng、Li Liu、Cheng Jiang

  DOI：10.1016/j.bmc.2021.116352

  日期：2021.9

  Aldehyde dehydrogenase 1A1 (ALDH1A1) plays vital physiological and toxicological functions in many areas, such as CNS, inflammation, metabolic disorders, and cancers. Overexpression of ALDH1A1 has been disclosed to play an important role in obesity, diabetes and other diseases, indicating the potential need for the identification and development of small molecule ALDH1A1 inhibitors. Herein, a series

  醛脱氢酶 1A1 (ALDH1A1) 在许多领域发挥重要的生理和毒理学功能，如中枢神经系统、炎症、代谢紊乱和癌症。已公开 ALDH1A1 的过度表达在肥胖、糖尿病和其他疾病中发挥重要作用，表明可能需要鉴定和开发小分子 ALDH1A1 抑制剂。在此，设计、合成和评价了一系列苯并咪唑衍生物。其中，化合物21，27，29，61和65表现出优异的抑制活性对ALDH1A1带IC 50在低微摩尔范围内的值和对 ALDH1A2、ALDH1A3、ALDH2 和 ALDH3A1 的高选择性。此外，一项体外研究表明，所有五种化合物都有效地改善了 HepG2 细胞的葡萄糖消耗，其中10 µM 的61和65产生的葡萄糖消耗与1 mM 的阳性对照二甲双胍(Met)产生的葡萄糖消耗几乎相等。此外，61和65在人肝微粒体中表现出理想的代谢稳定性。所有这些结果表明61和65适合进一步研究。
• Sustainable Synthesis of 2‐Hydroxymethylbenzimidazoles using D‐Fructose as a C ₂ Synthon
  作者：Dineshkumar Raja、Abigail Philips、Devikala Sundaramurthy、Gopal Chandru Senadi

  DOI：10.1002/asia.202100972

  日期：2021.11.15

  carbohydrate has been identified as an environmentally benign C2 synthon in the preparation of synthetically useful 2-hydroxymethylbenzimidazole derivatives by coupling with 1,2-phenylenediamines. The pivotal features of this method include metal-free conditions, short time, good functional group tolerance, gram scale feasibility and the synthesis of benzimidazole fused 1,4-oxazine.

  D-果糖是一种生物质衍生的碳水化合物，在通过与 1,2-苯二胺偶联制备合成有用的 2-羟甲基苯并咪唑衍生物时，已将其鉴定为环境无害的 C 2合成子。该方法的关键特征包括无金属条件、时间短、官能团耐受性好、克级可行性和苯并咪唑稠合 1,4-恶嗪的合成。
• Design, synthesis and biological evaluation of benzimidazole–rhodanine conjugates as potent topoisomerase II inhibitors
  作者：Penghui Li、Wenjin Zhang、Hong Jiang、Yongliang Li、Changzhi Dong、Huixiong Chen、Kun Zhang、Zhiyun Du

  DOI：10.1039/c8md00278a

  日期：——

  benzimidazole–rhodanine conjugates were designed, synthesized and investigated for their topoisomerase II (Topo II) inhibitory and cytotoxic activities. The results from Topo II-mediated pBR322 DNA relaxation and cleavage assays showed that the synthesized compounds might act as Topo II catalytic inhibitors. Certain compounds displayed potent Topo II inhibition at 10 μM. The cytotoxic activities of these compounds

  在这项研究中，设计，合成和研究了一系列苯并咪唑-罗丹宁偶联物的拓扑异构酶II（Topo II）抑制和细胞毒性活性。Topo II介导的pBR322 DNA弛豫和裂解试验的结果表明，合成的化合物可能充当Topo II催化抑制剂。某些化合物在10μM时显示出强力的Topo II抑制作用。评估了这些化合物对HeLa，A549，Raji，PC-3，MDA-MB-201和HL-60癌细胞系的细胞毒活性。结果表明这些化合物表现出很强的抗增殖活性。在Topo II抑制能力和这些化合物的细胞毒性之间观察到良好的关系。构效关系揭示了电子效应，苯基，
• Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists
  作者：Khaled M. Darwish、Ismail Salama、Samia Mostafa、Mohamed S. Gomaa、Mohamed A. Helal

  DOI：10.1016/j.ejmech.2015.12.049

  日期：2016.2

  Diabetes mellitus is a chronic metabolic disorder that affects more than 180 million people worldwide. Peroxisome proliferator activated receptors (PPARs) are a group of nuclear receptors that have been targeted by the thiazolidinedione (TZD) class of compounds for the management of type II diabetes. PPAR gamma is known to regulate adipogenesis and glucose metabolism. Another emerging target for the design of antidiabetic agents is the free fatty acid receptor 1 (FFAR1), previously known as GPR40. Agonists of this receptor were found to enhance insulin secretion in diabetic patients. It has been reported that some thiazolidinediones (TZDs) activate FFAR1 with micromolar potency. In this study, based on docking studies into the crystal structure of PPAR gamma and a homology model of FFAR1, nineteen compounds were designed, synthesized, and biologically tested for agonistic activity on both receptors. Nine compounds showed promising dual activity, with two compounds, 11a and 5b, having affinities in the low micromolar range on both targets. These molecules represent the first antidiabetic agents that could act as insulin sensitizers as well as insulin secretagogues. (C) 2015 Elsevier Masson SAS. All rights reserved.